The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Elanco Animal Health Inc (NYSE: ELAN) closed at $9.47 in the last session, down -0.11% from day before closing price of $9.48. In other words, the price has decreased by -$0.11 from its previous closing price. On the day, 3.22 million shares were traded. ELAN stock price reached its highest trading level at $9.64 during the session, while it also had its lowest trading level at $9.34.
Ratios:
We take a closer look at ELAN’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.93. For the most recent quarter (mrq), Quick Ratio is recorded 1.25 and its Current Ratio is at 2.44. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.72.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on December 09, 2024, initiated with a Buy rating and assigned the stock a target price of $18.
On December 02, 2024, Leerink Partners started tracking the stock assigning a Market Perform rating and target price of $14.
Morgan Stanley Downgraded its Overweight to Equal-Weight on September 19, 2024, whereas the target price for the stock was revised from $17 to $15.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 07 ’25 when Kurzius Lawrence Erik bought 10,000 shares for $10.90 per share. The transaction valued at 109,000 led to the insider holds 101,459 shares of the business.
Kurzius Lawrence Erik bought 10,000 shares of ELAN for $102,000 on Mar 11 ’25. The Director now owns 111,459 shares after completing the transaction at $10.20 per share. On Mar 05 ’25, another insider, HOOVER R DAVID, who serves as the Director of the company, bought 25,000 shares for $10.90 each. As a result, the insider paid 272,558 and bolstered with 210,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELAN now has a Market Capitalization of 4701457408 and an Enterprise Value of 8659993600. As of this moment, Elanco’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.96, and their Forward P/E ratio for the next fiscal year is 9.94. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.40. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.06 while its Price-to-Book (P/B) ratio in mrq is 0.77. Its current Enterprise Value per Revenue stands at 1.951 whereas that against EBITDA is 9.852.
Stock Price History:
The Beta on a monthly basis for ELAN is 1.50, which has changed by -0.30007392 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, ELAN has reached a high of $18.80, while it has fallen to a 52-week low of $8.02. The 50-Day Moving Average of the stock is -5.69%, while the 200-Day Moving Average is calculated to be -23.35%.
Shares Statistics:
According to the various share statistics, ELAN traded on average about 5.12M shares per day over the past 3-months and 4989060 shares per day over the past 10 days. A total of 494.45M shares are outstanding, with a floating share count of 491.76M. Insiders hold about 0.95% of the company’s shares, while institutions hold 99.33% stake in the company. Shares short for ELAN as of 1744675200 were 21852120 with a Short Ratio of 4.27, compared to 1741910400 on 14658581. Therefore, it implies a Short% of Shares Outstanding of 21852120 and a Short% of Float of 6.0900003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Currently, 10.0 analysts are dedicated to thoroughly evaluating and rating the performance of Elanco Animal Health Inc (ELAN) in the stock market.The consensus estimate for the next quarter is $0.25, with high estimates of $0.32 and low estimates of $0.22.
Analysts are recommending an EPS of between $1.0 and $0.76 for the fiscal current year, implying an average EPS of $0.83. EPS for the following year is $0.97, with 13.0 analysts recommending between $1.18 and $0.86.
Revenue Estimates
According to 8 analysts, the current quarter’s revenue is expected to be $1.17B. It ranges from a high estimate of $1.19B to a low estimate of $1.16B. As of the current estimate, Elanco Animal Health Inc’s year-ago sales were $1.21BFor the next quarter, 8 analysts are estimating revenue of $1.18B. There is a high estimate of $1.21B for the next quarter, whereas the lowest estimate is $1.14B.
A total of 11 analysts have provided revenue estimates for ELAN’s current fiscal year. The highest revenue estimate was $4.57B, while the lowest revenue estimate was $4.45B, resulting in an average revenue estimate of $4.5B. In the same quarter a year ago, actual revenue was $4.44BBased on 11 analysts’ estimates, the company’s revenue will be $4.69B in the next fiscal year. The high estimate is $4.74B and the low estimate is $4.63B.
